Cochrane · systematic review · CD007360
Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
Hwang, EC, Gandhi, S, Jung, JH, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
UrologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
21
current version
GRADE rated
16
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 5 · 23.8%Very low 2 · 9.5%Low 10 · 47.6%Moderate 4 · 19%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Naftopidil compared to tamsulosin (alpha‐blocker) for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (short term)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Urological symptom scores Naftopidil vs tamsulosin (alpha‐blocker) | no estimate extracted | 12 studies · 965 participants | Moderate Downgraded: risk of bias |
Quality of life Naftopidil vs tamsulosin (alpha‐blocker) | no estimate extracted | 11 studies · 878 participants | Low Downgraded: risk of bias |
Treatment withdrawals for any reason Naftopidil vs tamsulosin (alpha‐blocker) | RR 0.92 [0.64, 1.34] | 8 studies · 668 participants | Low Downgraded: risk of bias |
Cardiovascular adverse events Naftopidil vs tamsulosin (alpha‐blocker) | RR 0.97 [0.52, 1.8] | 9 studies · 824 participants | Low Downgraded: risk of bias |
Sexual adverse events Naftopidil vs tamsulosin (alpha‐blocker) | RR 0.54 [0.24, 1.22] | 5 studies · 397 participants | Low Downgraded: risk of bias |
Naftopidil compared to silodosin (alpha‐blocker) for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (short term)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Urological symptom scores Naftopidil vs silodosin (alpha‐blocker) | no estimate extracted | 5 studies · 652 participants | Low Downgraded: risk of bias |
Quality of life Naftopidil vs silodosin (alpha‐blocker) | no estimate extracted | 5 studies · 652 participants | Low Downgraded: risk of bias |
Treatment withdrawals for any reason Naftopidil vs silodosin (alpha‐blocker) | RR 0.8 [0.52, 1.23] | 4 studies · 659 participants | Low Downgraded: risk of bias |
Cardiovascular adverse events Naftopidil vs silodosin (alpha‐blocker) | RR 0.98 [0.39, 2.44] | 5 studies · 808 participants | Low Downgraded: risk of bias |
Sexual adverse events Naftopidil vs silodosin (alpha‐blocker) | RR 0.15 [0.06, 0.42] | 4 studies · 348 participants | Moderate Downgraded: risk of bias |
Naftopidil compared to propiverine (anticholinergic) for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (short term)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Urological symptom scores Naftopidil vs propiverine (anticholinergic) | no estimate extracted | 1 study · 37 participants | Low Downgraded: risk of bias |
Quality of life Naftopidil vs propiverine (anticholinergic) | no estimate extracted | 1 study · 37 participants | Low Downgraded: risk of bias |
Treatment withdrawals for any reasonc Naftopidil vs propiverine (anticholinergic) | no estimate extracted | 1 study · 37 participants | Ungraded |
Cardiovascular adverse eventsc Naftopidil vs propiverine (anticholinergic) | no estimate extracted | 1 study · 37 participants | Ungraded |
Sexual adverse eventsc Naftopidil vs propiverine (anticholinergic) | no estimate extracted | 1 study · 37 participants | Ungraded |
Naftopidil compared to Eviprostat (phytotherapy) for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (short term)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Urological symptom scores Naftopidil vs Eviprostat (phytotherapy) | no estimate extracted | 1 study · 49 participants | Moderate Downgraded: risk of bias |
Quality of life Naftopidil vs Eviprostat (phytotherapy) | no estimate extracted | 1 study · 49 participants | Moderate Downgraded: risk of bias |
Treatment withdrawals for any reason Naftopidil vs Eviprostat (phytotherapy) | no estimate extracted | 1 study · 49 participants | Very low Downgraded: risk of bias |
Treatment withdrawals due to adverse events Naftopidil vs Eviprostat (phytotherapy) | no estimate extracted | 1 study · 49 participants | Very low Downgraded: risk of bias |
Cardiovascular adverse eventsc Naftopidil vs Eviprostat (phytotherapy) | no estimate extracted | 1 study · 49 participants | Ungraded |
Sexual adverse eventsc Naftopidil vs Eviprostat (phytotherapy) | no estimate extracted | 1 study · 49 participants | Ungraded |